<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IFOSFAMIDE" rxcui="5657">
<ATC code="L01AA06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the neurotoxicity of the ifosfamide</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IFOSFAMIDE" rxcui="5657">
<ATC code="L01AA06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)" code="N03AA-001" /></DRUG2>
<DESCRIPTION>Risk of increase of the neurotoxicity of the ifosfamide due to increase of its hepatic metabolism by the phenobarbital</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="IFOSFAMIDE" rxcui="5657">
<ATC code="L01AA06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VEMURAFENIB" rxcui="1147220">
<ATC code="L01XE15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the ifosfamide, with increase of its active metabolite and increased toxicity</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>
